Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift

Editas has downgraded its outlook for its Reni-Cel and EDIT-401 programs, citing strategic shifts and discontinuation of certain clinical trials.

The company's earnings report showed a decline in revenue and earnings per share, driven by increased costs and lower demand for its gene editing products.